Stem cell transplants may halt the progression of aggressive multiple sclerosis in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests. Specifically, younger patients with a relapsing form of MS who were not severely disabled and who hadn’t found relief with other treatments fared better than others over five years, the international team of researchers found.